Global Malignant Ascites Treatment Market Is Expected To Reach USD 581.9 Mn By 2024: Credence Research
The latest market report published by Credence Research, Inc. “Global Malignant Ascites Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2024,”
(firmenpresse) - The latest market report published by Credence Research, Inc.
Browse the full report at http://www.credenceresearch.com/report/malignant-ascites-market
Market Insights
Malignant ascites indicates presence of malignant cells in the peritoneal cavity. The most common malignancies linked with development of malignant ascites are cancers of ovary, colon/rectum, breast, lung, liver, lungs and lymphoma. The survival rate of such patients is poor; however appropriate treatment modality can improve the quality of life. Approximately half of the patients with malignant ascites have peritoneal carcinomatosis with additional 30% patients with liver metastases leading to portal hypertension. Traditional therapies for malignant ascites include paracentesis, shunting, drugs such as spironolactone, catumaxomab, and chemotherapy. With the advent of monoclonal antibody for treatment of malignancies, the catumaxomab is being increasingly preferred in palliative care of malignant ascites. Among the available treatment options, paracentesis is the most preferred option with higher success rates. However associated health risks with repeated procedures, alternatives and adjuncts such as chemotherapy and catumaxomab are being highly preferred by physicians in developed markets
North America was observed as the leading geographical region in malignant ascites treatment market driven by key factors such as aging population coupled with cancer complications, rising prevalence of several cancers, strong treatment pipeline, and rising awareness in medical practitioners associated with complexities related to ascites. During the forecast period 2016 nesia, Australia and Thailand are expected to observed significant growth in the near future due to developing healthcare infrastructure, availability of highly skilled oncologists and upcoming research and development facilities.
Market Competition Assessment:
The malignant ascites market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are AstraZeneca plc, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems, Inc., Neovii Pharmaceuticals AG, Pfizer, Inc., Novartis AG, and GI Supply
Browse the full report at http://www.credenceresearch.com/report/malignant-ascites-market
Key Market Movements:
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: sales(at)credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.12.2017 - 07:34 Uhr
Sprache: Deutsch
News-ID 1530711
Anzahl Zeichen: 4524
contact information:
Contact person: David Colin
Town:
San Jose
Phone: 18003618290
Kategorie:
Automotive
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 638 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Global Malignant Ascites Treatment Market Is Expected To Reach USD 581.9 Mn By 2024: Credence Research
"
steht unter der journalistisch-redaktionellen Verantwortung von
Credence Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
